A new drug for fast-growing polycystic kidney disease
Part of Genetic & congenital, Kidney & urinary, Women’s health & pregnancy clinical trials.
This trial tests a drug (JMKX003142) for people with autosomal dominant polycystic kidney disease that is getting worse quickly. It may help slow down kidney damage.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have a type of kidney disease called ADPKD that is rapidly getting worse.
- You are between 18 and 55 years old.
- You have not taken tolvaptan or other ADPKD treatments in the last 3 months.
- You can feel thirst and have no trouble eating or drinking.
- You have not had surgery to remove kidney cysts or major surgery in the last 3 months.
- You are willing and able to follow the study rules.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study is for healthy volunteers to see how a new experimental drug (JMKX003142) interacts with other drugs in the body. It helps find the right dose for future patients.
This study looks at how a new drug (JMKX003142) is absorbed and broken down in the body. It involves healthy men and will help determine safe dosing for future studies.
This trial tests how a new drug (JMKX003142) interacts with other substances in healthy volunteers. It helps researchers understand how the drug is absorbed and processed, which is a key step before it can be tested in patients.
This study tests a new medicine (JMKX003142) in healthy adults to see if it affects the heart's rhythm. If you qualify, you may help determine whether the drug is safe to use in future patients.
This study tests a new investigational drug called GV-100 to see how safe it is and how the body handles it. It is for healthy adults and will be given in different doses to find the best one.
This trial tests if the cholesterol-lowering drug bempedoic acid can slow kidney function loss in people with autosomal dominant polycystic kidney disease (ADPKD). It may offer a new option to protect your kidneys.
Hear when a new ADPKD (Autosomal Dominant Polycystic Kidney Disease) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.